Table 1.
Benralizumab: summary of the main phase 3 clinical trials.
| Authors and trial name | Duration | Number of patients | Main results |
|---|---|---|---|
| Bleecker et al. (2016) [23], SIROCCO | 48 weeks | 1205 | Fewer asthma exacerbations, higher FEV1 |
| FitzGerald et al. (2016) [24], CALIMA | 56 weeks | 1306 | Fewer asthma exacerbations, higher FEV1 |
| Nair et al. (2017) [25], ZONDA | 28 weeks | 220 | Lower intake of oral corticosteroids, fewer asthma exacerbations |
| Ferguson et al. (2017) [26], BISE | 12 weeks | 211 | Smaller numbers of blood eosinophils |